States Say AMG Case Can't Save Drugmakers In Price-Fix Suit

By Christopher Cole (December 3, 2021, 7:16 PM EST) -- State enforcers have told a Pennsylvania federal judge that this year's U.S. Supreme Court decision to pare the Federal Trade Commission's use of restitution powers has no impact on their pursuit of price-fixing damages against generic-drug makers.

Led by the Connecticut Attorney General's Office, the states argued that the justices' unanimous ruling this spring in AMG Capital v. FTC, which swept away the commission's long-running use of federal court-ordered injunctions to obtain monetary relief for antitrust and consumer harms, does not dash their Clayton Act claims for relief against the pharma companies.

The states' suit is only part of multidistrict litigation...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!